Strides Pharma Science Limited at its meeting held on May 22, 2023 approved changes in Management of the Company by the Board of Directors of the Company based on the recommendations of Nomination and Remuneration Committee. The Company changed designation of Mr. Badree Komandur from Group CFO to MD & Group CEO. The company changed designation of Mr. Vikesh Kumar from CFO - Front End Markets to Group CFO.

Appointment of Mr. Vikesh Kumar as Group CFO of the Company effective June 1, 2024. Consequently, he is also classified as KMP of the Company effective June 1, 2024. Vikesh is currently CFO of the Front-End Markets.

Mr. Vikesh Kumar, aged 39 years, holds a Post Graduate Diploma in Management (PGDM) from S.P Jain Institute of Management & Research, Mumbai. Vikesh has over 15 years of rich and comprehensive experience in Business Finance, Mergers & Acquisitions, Treasury, Forex Management, Fund Raising, Governance and Investor Relations Management, amongst others. Vikesh is associated with Strides since June 2009, joining as part of the campus recruitments for the Strides Leadership program of 2009.

During his tenure at Strides, he has built and led the business finance function for the group, building it as the nerve centre of the organization, partnering business and functional heads in executing the company's plans. He also has played lead roles in Mergers & Acquisitions, Governance, Fund Raising, Treasury, Forex Management and Investor Relations Management, amongst others. Prior to his appointment as CFO for the Front-End businesses in May 2022, Vikesh was the Head of Business Finance for the group.

In his role as the CFO for the Front-End businesses, he relocated to the US in August 2023, to drive the reset strategy in the geography with focus on building profitable, sustainable cash generating operations. As part of the leadership team in the US, he led the revival of Chestnut Ridge manufacturing operations and enabled the company to set industry leading benchmarks in the Front-End operations.